肝细胞癌的非病毒病因
Non-viral causes of hepatocellular carcinoma.
作者信息
Van Thiel David H, Ramadori Guiliano
机构信息
Rush University Medical Center, Chicago, IL 60612, USA.
出版信息
J Gastrointest Cancer. 2011 Dec;42(4):191-4. doi: 10.1007/s12029-010-9195-3.
Abstract
INTRODUCTION
Hepatocellular carcinoma (HCC) is a major cause of cancer worldwide. The vast majority of cases occur in individuals with a chronic HBV or HCV infection. In addition, a number of metabolic diseases of the liver are associated with the development of HCC.
PATHOPHYSIOLOGIC MECHANISMS
The mechanisms responsible for the progression of the metabolic liver disease and HCC differ from those associated with viral liver disease.
CONCLUSIONS
The purpose of this report is to describe the mechanisms responsible for the disease progression and HCC in case of metabolic liver disease. A secondary goal is to identify the frequency of HCC development in the disorders described.
摘要
引言
肝细胞癌（HCC）是全球癌症的主要病因。绝大多数病例发生在慢性乙肝或丙肝感染患者中。此外，一些肝脏代谢性疾病与HCC的发生有关。
病理生理机制
代谢性肝病和HCC进展的机制与病毒性肝病相关机制不同。
结论
本报告的目的是描述代谢性肝病时疾病进展和HCC的相关机制。第二个目标是确定所描述疾病中HCC发生的频率。
相似文献
1
Non-viral causes of hepatocellular carcinoma.
J Gastrointest Cancer. 2011 Dec;42(4):191-4. doi: 10.1007/s12029-010-9195-3.
2
Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma.
J Clin Gastroenterol. 2005 Aug;39(7):611-8. doi: 10.1097/01.mcg.0000170770.49394.92.
3
A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Int J Epidemiol. 1998 Aug;27(4):574-8. doi: 10.1093/ije/27.4.574.
4
Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease.
J Clin Lab Anal. 2020 Feb;34(2):e23075. doi: 10.1002/jcla.23075. Epub 2019 Oct 28.
5
Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma.
BMC Cancer. 2013 Jul 8;13:335. doi: 10.1186/1471-2407-13-335.
6
A case of hepatocellular carcinoma in normal liver with no evidence of HBV or HCV infection.
Hepatogastroenterology. 1996 Sep-Oct;43(11):1390-4.
7
Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins.
Int J Mol Sci. 2021 Oct 13;22(20):11051. doi: 10.3390/ijms222011051.
8
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.
Semin Cancer Biol. 2014 Jun;26:78-88. doi: 10.1016/j.semcancer.2014.01.004. Epub 2014 Jan 20.
9
Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
J Pathol. 2000 Oct;192(2):207-15. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH690>3.0.CO;2-#.
10
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
Princess Takamatsu Symp. 1995;25:27-32.
引用本文的文献
1
The Influence of Residential Segregation, Urbanicity, and Population Density on Hepatocellular Carcinoma Incidence among a Low Socioeconomic Population.
Cancer Epidemiol Biomarkers Prev. 2025 Feb 6;34(2):348-354. doi: 10.1158/1055-9965.EPI-24-1119.
2
Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma.
World J Gastroenterol. 2024 May 28;30(20):2624-2628. doi: 10.3748/wjg.v30.i20.2624.
3
A Novel Four-Gene Signature Based on Nonsense-Mediated RNA Decay for Predicting Prognosis in Hepatocellular Carcinoma: Bioinformatics Analysis and Functional Validation.
J Hepatocell Carcinoma. 2024 Apr 23;11:747-766. doi: 10.2147/JHC.S450711. eCollection 2024.
4
Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024 Mar 19;11:581-594. doi: 10.2147/JHC.S450460. eCollection 2024.
5
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma.
Clin Mol Hepatol. 2024 Jul;30(3):360-374. doi: 10.3350/cmh.2024.0042. Epub 2024 Mar 15.
6
Liver disease with unknown etiology - have you ruled out alpha-1 antitrypsin deficiency?
Ther Adv Chronic Dis. 2021 Jul 29;12_suppl:2040622321995684. doi: 10.1177/2040622321995684. eCollection 2021.
7
Racial Differences in Hepatocellular Carcinoma Incidence and Risk Factors among a Low Socioeconomic Population.
Cancers (Basel). 2021 Jul 23;13(15):3710. doi: 10.3390/cancers13153710.
8
Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.
Semin Liver Dis. 2019 May;39(2):261-274. doi: 10.1055/s-0039-1678725. Epub 2019 Mar 25.
9
Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome.
J Expo Sci Environ Epidemiol. 2015 May;25(3):256-63. doi: 10.1038/jes.2014.16. Epub 2014 Apr 16.
10
An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations.
PLoS One. 2013 Jun 28;8(6):e67756. doi: 10.1371/journal.pone.0067756. Print 2013.
本文引用的文献
1
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
J Hepatol. 2010 Apr;52(4):550-9. doi: 10.1016/j.jhep.2010.01.015. Epub 2010 Feb 13.
2
The metabolic syndrome--a new worldwide definition.
Lancet. 2005;366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8.
3
Epidemiology of hepatocellular carcinoma.
Clin Liver Dis. 2005 May;9(2):191-211, v. doi: 10.1016/j.cld.2004.12.009.
4
Primary liver cancer: worldwide incidence and trends.
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16. doi: 10.1053/j.gastro.2004.09.011.
5
Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960.
Int J Cancer. 2004 Jun 10;110(2):155-69. doi: 10.1002/ijc.20097.
6
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.
Ann Intern Med. 2003 Nov 18;139(10):817-23. doi: 10.7326/0003-4819-139-10-200311180-00009.
7
Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study.
J Clin Gastroenterol. 2003 Apr;36(4):356-9. doi: 10.1097/00004836-200304000-00015.
8
Oxidants and antioxidants in alcohol-induced liver disease.
Gastroenterology. 2003 Mar;124(3):778-90. doi: 10.1053/gast.2003.50087.
9
Changing international trends in mortality rates for liver, biliary and pancreatic tumours.
J Hepatol. 2002 Dec;37(6):806-13. doi: 10.1016/s0168-8278(02)00297-0.
10
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15584-9. doi: 10.1073/pnas.242608099. Epub 2002 Nov 18.
Zotero 插件